Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Air Products & Chemicals, Inc. (APD) vs ResMed Inc. (RMD) Price & Performance

Air Products & Chemicals, Inc.
ResMed Inc.

Price performance

Price movement over the last 24 hours

Key statistics

Air Products & Chemicals, Inc. vs ResMed Inc. — how do they compare? Air Products & Chemicals, Inc. trades at $296.7 (market cap $66.70B), while ResMed Inc. trades at $198.7 (market cap $29.57B). The key difference: Air Products & Chemicals, Inc. is far larger — about 2.3× ResMed Inc.'s market cap, and Air Products & Chemicals, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.

APDRMD
Market Cap
$66.70B$29.57B
Sector
Basic MaterialsHealth
52-Week High
$314.19$293.73
52-Week Low
$230.42$182.82
Enterprise Value
$84.11B$28.76B
Dividend Yield
2.42%1.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Air Products & Chemicals, Inc.

APD trades at $299.53, up 1.24% today, with a bullish technical signal from moving averages and strong analyst support. Recent earnings beats and strategic project exits, like the Louisiana Clean Energy Complex, have boosted investor confidence. The company maintains solid profitability margins but faces pressure from a negative net income in 2025 due to a pre-tax charge. Cash flow trends show volatility, with significant investing outflows for growth initiatives.

The outlook is positive with a consensus price target of $324.89, implying ~8% upside. Risks include high debt levels, execution on new projects, and macroeconomic sensitivity. Long-term growth is supported by renewable energy investments, but near-term profitability recovery is key for sustained gains.

ResMed Inc.

ResMed (RMD) trades at $203.87, down 2.2% today, but maintains strong fundamentals with consistent earnings beats and robust profitability. The company recently sold its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets. Technical indicators show a bullish trend with support at $202, while fundamentals reveal impressive 27.4% net margins and steady revenue growth from $5.15B in 2025 to projected $5.5B in 2026.

RMD presents a compelling investment case with 28% upside to analyst consensus target of $254.57, supported by strong cash flow generation and strategic business optimization. Key risks include competitive pressures in the sleep apnea market and potential market share challenges from new pharmaceutical treatments. The balanced analyst coverage (15 Buy, 15 Hold, 5 Sell) suggests cautious optimism amid the company's solid execution and growth trajectory.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Air Products & Chemicals, Inc.

Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.

Read more on APD

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD